抗抑郁藥阿戈美拉汀doc-資料下載頁
2025-07-15 06:13本頁面
【正文】 avis LL, Wisniewski SR, Howland RH, et al. Does orbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STARD level one treatment outes. Drug Alcohol Depend. 2010。107:161–170.[PubMed][9] Silverstein B, Patel P. Poor response to antidepressant medication of patients with depression acpanied by somatic symptomatology in the STARD study. Psychiatry Res. 2011。187:121–124.[PubMed][10] San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008。23:396–402.[PubMed][11] Wikipedia Agomelatine. [May 3, 2011]. [12] Servier Laboratories [May 3, 2011]。Valdoxan. [13] Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007。10:575–578.[PubMed][14] Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, doubleblind parison with venlafaxine. J Clin Psychiatry. 2007。68:1723–1732.[PubMed][15] Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5HT2c antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007。10:661–673.[PubMed]
規(guī)章制度相關(guān)推薦
鄂ICP備17016276號-1